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Abstract
A number of antibodies that efficiently neutralize microbial targets contain long heavy chain complementarity determining
region 3 (HCDR3) loops. For HIV, several of the most broad and potently neutralizing antibodies have exceptionally long
HCDR3s. Two broad potently neutralizing HIV-specific antibodies, PG9 and PG16, exhibit secondary structure. Two other
long HCDR3 antibodies, 2F5 and 4E10, protect against mucosal challenge with SHIV. Induction of such long HCDR3
antibodies may be critical to the design of an effective vaccine strategy for HIV and other pathogens, however it is unclear
at present how to induce such antibodies. Here, we present genetic evidence that human peripheral blood antibodies
containing long HCDR3s are not primarily generated by insertions introduced during the somatic hypermutation process.
Instead, they are typically formed by processes occurring as part of the original recombination event. Thus, the response of
B cells encoding antibodies with long HCDR3s results from selection of unusual clones from the naı ¨ve repertoire rather than
through accumulation of insertions. These antibodies typically use a small subset of D and J gene segments that are
particularly suited to encoding long HCDR3s, resulting in the incorporation of highly conserved genetic elements in the
majority of antibody sequences encoding long HCDR3s.
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Introduction
Antibodies containing long heavy chain complementarity de-
termining region 3 (HCDR3) loops have been shown to efficiently
neutralize a widevariety ofpathogens, including HIV, malaria, and
Africantrypanosomes[1–3].Insomecases,theuniquefeatureoflong
HCDR3 antibodies is that the extended loop structure facilitates
interaction with epitopes that are otherwise occult because of
extensive glycosylation or location in recessed structures on the
pathogensurface.Formalaria,antibodiescontaininglongHCDR3s
havebeenidentifiedthatbindbyextendingdeepintoahydrophobic
cleft on apical membrane antigen 1 (AMA1) to contact highly
conserved hydrophobic residues [2]. For HIV, several of the most
broad and potently neutralizing antibodies have extremely long
HCDR3 loops. Two exceptionally broad and potent anti-HIV
antibodies, PG9 and PG16, encode among the longest human
antigen-specific antibodies described to date and form secondary
structurethroughtheuseofacomplexhydrogenbondingnetworkin
the HCDR3 [4,5]. These antibodies target a currently undefined
quaternary epitope and preferentially bind cell surface expressed
trimeric envelope protein [6,7]. Two additional HIV antibodies,
designated 2.5b and 2909, target a similar quaternary epitope and
containlongHCDR3s,butareabletoneutralizeonlyaverylimited
panelofvirusisolates[8,9].Apanelofrecentlydescribedantibodies,
PGT141-PGT145, are purported to target the same quaternary
epitope as PG9 and PG16, have a similar strong preference for
membrane-bound,trimericenvelope,andencodeHCDR3sthatare
even longer than the exceptionally long HCDR3s seen in PG9 and
PG16 [10]. The broadly neutralizing HIV antibody b12 contains
a long HCDR3 and is able to neutralize by targeting the conserved
CD4 binding site [11–13]. The b12 antibody uses only heavy chain
interactions at the antigen binding interface, and passive adminis-
tration of b12 has been shown to be protective against low-dose
repeated challenge in macaques [14,15]. Two other broadly
neutralizing antibodies with long HCDR3s, 4E10 and 2F5, target
a conserved membrane-proximal region and have been shown to
protect against mucosal SHIV challenge alone and in combination
withtheanti-HIVantibody2G12[16–19],andthelongHCDR3of
2F5 is critical to the neutralizing ability of 2F5 [20]. Antibody 447-
52D contains a long HCDR3 loop and is able to neutralize a broad
range of clade B HIV-1 isolates by targeting a conserved epitope on
theV3loopofgp120[21,22].Finally,theneutralizingantibody17b
targetstheHIVco-receptorbindingsiteandfacilitatesneutralization
by preventing co-receptor binding and reducing affinity for the
primary receptor, cluster of differentiation 4 (CD4) [23]. Thus,
antibodies containing long HCDR3s comprise a sizeable fraction of
theneutralizingHIVantibodiesdescribedtodate,includingmanyof
the mostbroad and potently neutralizingantibodies.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36750Although induction of such long HCDR3 antibodies is likely to
be critical to the design of an effective HIV vaccine strategy, it is
still unclear how to induce such antibodies. Previous work has
speculated as to a potential mechanism for inducing such
antibodies by vaccination [5,24]. It is known that the affinity
maturation process is associated with codon-length insertion
events that are likely caused by the somatic hypermutation
machinery [25–27]. It is thought, then, that repeated rounds of
affinity maturation, resulting in multiple short insertion events
within the HCDR3, could gradually lengthen HCDR3 loops in
the affinity matured antibodies. This observation fits well with the
known kinetics of broadly neutralizing antibody generation during
HIV infection: potently neutralizing HIV antibodies are produced
later than is common in other viral infections [28,29], suggesting
that many rounds of affinity maturation may be necessary to
develop broad and potent neutralizing capacity.
We considered that it is also possible that long HCDR3 loops
are not generated primarily through the affinity maturation
process, however, and are instead primarily created during the
recombination process through the introduction of extensive
numbers of N- and P-insertions and the selective use of optimal
germline gene segments. If the primary source of long HCDR3
antibodies in the peripheral blood is not affinity maturation, the
process of inducing an antibody response containing antibodies
with long HCDR3s would consist of exhaustive sampling of the
repertoire to select those B cells encoding what are, presumably,
rare antibodies [5,7]. While it has previously been shown that
antibodies containing long HCDR3s are present in immature B
cell populations in both man [30] and mouse [31,32] as well as in
human perinatal liver [33], it is unclear how frequently these
antibodies are able to successfully navigate the autoreactivity
screening process and enter the mature B cell population.
Extensive work has been done in characterizing short and long
HCDR3s in mice [34–36], but much of the work was done model
systems under non-physiologic conditions. An examination of
hundreds of thousands of circulating human antibody sequences
has identified an upper limit to the number of unique HCDR3s in
a single individual [37]. The upper bound, 3 to 9 million unique
HCDR3s per individual, is much lower than previously estimated,
but this study did not describe the length distribution of these
HCDR3s. It has been shown that many B cells encoding HCDR3s
of extreme length are eliminated before reaching the periphery
[30], likely because antibodies with long HCDR3s have auto-
reactive properties [38–41]. Detailed study and genetic charac-
terization of the long HCDR3 antibody population in human
peripheral blood has been limited by the rarity of such sequences.
In this study, we examined expressed antibody sequences from
four healthy donors and determined that antibodies containing
long HCDR3s are more common in the naı ¨ve subset than in
memory, indicating that affinity maturation is not the primary
source of such antibodies. Further, extensive genetic character-
ization identified several conserved sequence elements in the long
HCDR3 peripheral blood antibody population. Thus, human
peripheral blood antibodies containing long HCDR3s are not
generated primarily through repetitive rounds of affinity matura-
tion, but are typically formed at the time of the original
recombination.
Results
Increased HCDR3 Length was not Associated with an
Increased Number of Somatic Mutations or Insertions
We considered three major subsets of B cells in the peripheral
blood: naı ¨ve B cells, which are antigen inexperienced and lack
somatic mutations or class-switching; IgM memory B cells, which
express the surface memory marker CD27 and show evidence of
somatic hypermutation but not class-switching; and IgG memory
cells, which express CD27 and have undergone both somatic
hypermutation and class-switching. We separately isolated naı ¨ve,
IgM memory and IgG memory B cells from four healthy
individuals (hereafter, designated Group 1) using flow cytometric
sorting and subjected the transcribed antibody heavy chain genes
from those cells to high throughput sequencing. After selecting
only non-redundant, high-quality antibody sequences, we ob-
tained a total of 294,232 naı ¨ve cell sequences, 161,313 IgM
memory cell sequences and 94,841 IgG memory cell sequences
from Group 1 donors. We also subjected the transcribed
peripheral blood heavy chain antibody genes of three additional
healthy donors (hereafter, designated Group 2) and four HIV-
infected donors to high throughput sequencing. The B cells from
these additional donors were not sorted by B cell subset prior to
sequencing, but instead represent a sampling of the total
peripheral blood B cell repertoire from each donor. The number
of non-redundant, high-quality sequences obtained from each of
the Group 2 and HIV-infected donors is shown in Table S2.
Peripheral blood antibody sequences from Group 1 and Group
2 healthy donors were grouped by mutation frequency, and the
fraction of sequences containing insertions was determined for
each group (Figure 1A, left panel). In agreement with previously
published data [25], we observed a strong positive correlation
between number of mutations and insertion frequency (r
2=0.77,
p,0.0001). Insertions were present only in a minority of the most
highly mutated sequences, however, suggesting either that the
somatic hypermutation process is inefficient at introducing
insertions in a functional reading frame or that antibodies seldom
are able to tolerate genetic insertions while retaining functionality.
When separately analyzing each of the B cell subsets from Group 1
healthy donors, we observed that the correlation between
mutations and insertions also was found for each of the memory
B cell subsets (Figure 1A, right panel).
We next grouped the sequences by HCDR3 length and de-
terminedthemeannumberofmutationsandinsertionfrequencyfor
each HCDR3 length group (Figure 1B, left panels). Interestingly,
HCDR3 length was negatively correlated with both mutation
frequency (r
2=0.64, p,0.0001) and insertion frequency (r
2=0.13,
p,0.0001),suggestingthatgeneticprocessesthataccomplishsomatic
hypermutationtypicallydonotalterHCDR3length.Asimilartrend
was seen in each of the Group 1 healthy donor B cell subsets
(Figure1B,rightpanels).Ithasbeenshownpreviouslythatthemean
HCDR3lengthincirculatingmemoryBcellsubsetsisshorterthanin
the naı ¨ve B cell subset by approximately a single amino acid [42].
Analyzing the mean HCDR3 length, however, does not allow
determination of whether there is a broadly-distributed, overall
shortening of the entire HCDR3 repertoire (perhaps caused by
somatichypermuation-induceddeletionsintheHCDR3thatreduce
the length of both long and short HCDR3s) or whether the lower
mean HCDR3 length in memory is predominantly due to a strong
preference against long HCDR3s in the memory subset. We
examined the antibody sequences from naı ¨ve, IgM memory, and
IgGmemoryBcellsubsetsfromGroup1healthydonorsforpresence
oflongHCDR3s(definedhereasHCDR3s$24aminoacids,which
corresponds to 2 SD above the mean HCDR3 length) and for very
long HCDR3s (defined here as HCDR3s $28 amino acids, which
corresponds to 3 SD above the mean HCDR3 length). The naı ¨ve
populationcontainedasignificantlyhigherfractionoflongHCDR3s
(3.5%, Figure 1C) than both the IgM memory subset (0.74%,
p=0.0003)andtheIgGmemorysubset(1.9%,p=0.014).Thenaı ¨ve
subset also contained a significantly higher fraction of very long
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36750Figure 1. Increased HCDR3 length does not correlate with affinity maturation events. (A) Peripheral blood antibody sequences were
grouped by mutation frequency and the percent of sequences in each group that contained codon-length (non-frameshift) insertions was calculated
for each donor. All values for healthy donors from Group 1 (n=4) and Group 2 (n=3) are shown in the left panel, with the mean percentage 6 SEM
shown for each mutation value. In the right panel, sequences from Group 1 healthy donors were segregated by B cell subset, and the best-fit linear
regression for each subset is shown. (B) Peripheral blood antibody sequences were grouped by HCDR3 length (in amino acids) and the mean number
of mutations for each HCDR3 length group was calculated for each donor. As in Figure 1A, the left panel shows the mean 6 SEM for all donors in
Group 1 and Group 2. The right panel shows the best-fit linear regression of each B cell subset for Group 1 donors. The percent of sequences within
each HCDR3 length group containing non-frameshift insertions also was calculated. In the left panel, the mean percentage 6 SEM for all donors in
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36750HCDR3s (0.43%, Figure 1D) than either the IgM memory subset
(0.06%, p=0.001) or the IgG memory subset (0.19%, p=0.038).
Interestingly,theIgMmemorysubsetshowedasignificantlyreduced
frequency of long HCDR3s when compared with the IgG memory
subset (p=0.0056), which supports emerging data that the IgM
memory subset does not function primarily as a transition state in
progression from the naı ¨ve to IgG memory repertoire [42]. In
summary, introduction of point mutations and insertions during
somatic hypermutation had little effect on HCDR3 length, and we
notedthesomewhatsurprisingpresenceofalargepopulationoflong
HCDR3s in the naı ¨ve repertoire. These data suggested that long
HCDR3sarenotbuiltprimarilythroughrepeatedroundsofaffinity
maturation using genetic insertions, but are present in the naı ¨ve
repertoire beforeB cells begin the affinity maturation process.
Antibody Sequences Encoding Long or Very Long
HCDR3s Display Skewed Germline Gene Usage
With the understanding that long HCDR3s are not produced
primarily by the affinity maturation process, we examined the
antibody repertoire for evidence of recombination events that
correlate with HCDR3 length. First, we grouped the peripheral
blood antibody sequences from each Group 1 and Group 2
healthy donor by three criteria: (1) all HCDR3s, which included
all antibodies containing any HCDR3 length; (2) long HCDR3s,
which included only sequences with HCDR3 lengths $24 amino
acids long; and (3) very long HCDR3s, which included only
sequences with HCDR3 lengths $28 amino acids long.
We analyzed the germline V, D and J gene segment use in each
of the three sequence groups (Figure 2). The most remarkable
finding noted was the strong association of two particular D gene
families and one J gene segment with longer HCDR3s. Use of D
gene families D2 and D3 was increased in long HCDR3s (both D2
and D3: p,0.001) and very long HCDR3s (both D2 and D3:
p,0.001). A significant decrease in use of D gene family D6 was
seen in long and very long HCDR3s (p,0.01), and a decrease in
D1 gene family use was seen in long HCDR3s (p,0.01). Use of J
gene JH6 was increased markedly in both long (p,0.001) and very
long HCDR3s (p,0.001), while joining gene JH4 use was
decreased in long (p,0.001) and very long HCDR3s (p,0.001).
This was not surprising, considering that JH6 is the longest JH gene
segment and JH4 is the shortest. Interestingly, however, use of JH1
and JH2, which are two amino acids longer than JH4, was not
increased significantly in long or very long HCDR3 groups. We
also noted some variation in VH gene usage. Use of variable gene
family VH1 was increased in the long HCDR3 (p,0.05) and very
long HCDR3 (p,0.05) groups compared to the group with all
HCDR3 lengths (p,0.05). VH3 family use was decreased in long
HCDR3s (p,0.05) but not in the very long HCDR3 group.
Separate analysis of the individual B cell subsets in Group 1 donors
indicated that the trends observed for the total repertoire were
largely mirrored in each subset repertoire (Figures S1,S2,S3).
Deeper analysis of individual D gene use (as opposed to analysis
of the D gene families shown in Figure 2) revealed that the increase
in D2 and D3 gene families is driven almost completely by
increased use of just three of the nine D2 and D3 gene family
members: D2-2, D2-15 and D3-3 (Figure S4A). Separate analysis
of the frequency of the three D genes that were increased in the
total repertoire in each B cell subset (Figure S4B-D) showed similar
trends, although the reduced sample size of each subset, as well as
the infrequency of long HCDR3s in both memory subsets, resulted
in trends that were less robust. The pattern of diversity gene use in
long HCDR3s was somewhat surprising, since D3-16, which is not
increased in long or very long HCDR3s, is two amino acids longer
than any of the three preferred D genes. Further, four additional D
genes, D2-8, D3-9, D3-10 and D3-22 are the same length as the
three preferred genes, but are not significantly more common in
long or very long HCDR3s than in the total repertoire. Thus,
while the D2 and D3 gene families encode the longest D genes
found in the repertoire, the increased frequency of only a select
few of the diversity genes in these families indicates that length is
not the only factor driving the increased frequency of these D gene
segments in long and very long HCDR3 repertoires.
Increased HCDR3 Length Correlated with Genetic
Features Associated with Recombination
We next grouped all of the peripheral blood antibody sequences
from Group 1 and Group 2 healthy donors by HCDR3 length and
determined the average N-addition length and P-addition length
(Figure 3A, left panels) for each HCDR3 length group. Both
features showed positive correlations, with N-addition increasing
exponentially (r
2=0.96) and P-addition increasing linearly
(r
2=0.35, p,0.0001) with increasing HCDR3 length. Similar
correlations were seen when analyzing individual B cell subsets
from Group 1 healthy donors (Figure 3A, middle panels) and
peripheral blood antibody sequences from HIV-infected donors
(Figure 3A, right panels).
Following the observation that germline gene usage was
skewed in long HCDR3s (Figure 2), we examined the use of
D2/D3 (i.e., D2 or D3) family genes as a combined group more
closely. We first examined peripheral blood antibody sequences
from Group 1 and Group 2 healthy donors (Figure 3B, left
panel), and non-linear regression analysis revealed a sigmoidal
correlation between D2/D3 gene use (r
2=0.80) and HCDR3
length, with combined D2/D3 gene use exceeding 80% in the
longest HCDR3s. The increased use of D2/D3 genes was not
surprising, as the D2 and D3 nucleotide sequences are the
longest in diversity gene families. This correlation also was seen
when analyzing the individual subsets of Group 1 healthy
donors (Figure 3B, middle panel) and peripheral blood antibody
sequences from HIV-infected donors (Figure 3B, right panel;
r
2=0.61). Analysis of JH6 gene use in the peripheral blood
antibody repertoire of Group 1 and Group 2 healthy donors
(Figure 3B, left panel) revealed a sigmoidal correlation between
JH6 gene use and increasing HCDR3 length (r
2=0.87). JH6 was
used in less than 10% of the shortest HCDR3s, but was present
in over 75% of the longest HCDR3s. We observed a similar
correlation when analyzing the individual subsets of Group 1
healthy donors (Figure 3C, middle panel) and peripheral blood
antibody sequences from HIV-infected donors (Figure 3C, right
panel; r
2=0.83). The observed preference for JH6 was expected,
as JH6 is by far the longest J gene, adding as many as five more
codons to the HCDR3 than the shortest J genes. We also
Group 1 and Group 2 is shown. In the right panel, the best-fit linear regression of each B cell subset is shown for Group 1 donors. (C) Peripheral blood
antibody sequences from Group 1 healthy donors were grouped by donor into naı ¨ve and memory subsets and the percent of sequences containing
long HCDR3s ($24 amino acids in length, or two standard deviations above the mean HCDR3 length). The percentages for each donor are shown,
with the mean 6 SEM. (D) The donor groups from Figure 1C were analyzed for the frequency of very long HCDR3s ($28 amino acids in length, i.e.,
three standard deviations above the mean HCDR3 length). The percentages for each donor are shown, with the mean 6 SEM. The p values were
determined using a one-way ANOVA. All statistically significant differences are indicated. *=p,0.05, **=p,0.01, ***=p,0.001.
doi:10.1371/journal.pone.0036750.g001
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Group 2 healthy donors to determine the frequency of
sequences that use both JH6 and D2/D3 genes (Figure 3D,
left panel) and found a strong sigmoidal correlation between
combined JH6 and D2/D3 use (r
2=0.81). While combined JH6
and D2/D3 use was unusual in the shortest HCDR3s (3.0%),
D2-JH6 and D3-JH6 encoded antibodies comprised the majority
of the repertoire of the longest of HCDR3s (58.8%). The trend
toward increased use of JH6 and D2/D3 also was seen in
individual subsets of Group 1 healthy donors (Figure 3D,
middle panel) and in HIV-infected donors (Figure 3D, right
panel; r
2=0.81). Further analysis of Group 1 and Group 2
healthy donors revealed a correlation between HCDR3 length
and use of JH6 in sequences that do not incorporate D2/D3
(Figure S5A) and between HCDR3 length and in use of D2/D3
in sequences that do not incorporate JH6 (Figure S5B), but the
positive correlation only extended to HCDR3 lengths of
approximately 20 amino acids. This finding suggested that
while use of one germline gene (either JH6 or D2/D3) is
sufficient to allow generation of relatively long HCDR3s, both
germline genes are required to generate the longest HCDR3s.
Diversity Gene Reading Frame 2 is Used Preferentially in
Long HCDR3s
We next analyzed the reading frame preferences in long
HCDR3s. We used the ImMunoGeneTics (IMGT) method for
calculating the D gene reading frame, which determines the
reading frame based on the first codon of the D gene nucleotide
sequence. The functional reading frame equivalent to IMGT
Figure 2. Skewed germline gene usage in antibodies containing long or very long HCDR3s. Peripheral blood antibody sequences from
Group 1 (n=4) and Group 2 (n=3) healthy donors were assembled into the following three groups by HCDR3 length: (1) all HCDR3s, which contains
all sequences of any HCDR3 length; (2) long HCDR3s, which contains only sequences with a HCDR3 length $24 amino acids; and (3) very long
HCDR3s, which contains only sequences with a HCDR3 length $28 amino acids. The frequency of each germline variable gene family, diversity gene
family, and joining gene was determined for each HCDR3 length group. The mean frequency 6 SEM is shown. All HCDR3 lengths were calculated
using the IMGT numbering system. The p values were determined using a two-way ANOVA with Bonferroni post-tests. All statistically significant
differences are indicated. *=p,0.05, **=p,0.01, ***=p,0.001.
doi:10.1371/journal.pone.0036750.g002
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36750Figure 3. Long HCDR3s correlate with N-addition, P-addition and germline gene usage. For all figure sections, the leftmost panel
corresponds to peripheral blood antibody sequences from Group 1 (n=4) and Group 2 (n=3) healthy donors. The middle panel corresponds to
antibody sequences from Group 1 donors, segregated by B cell subset. The rightmost panel corresponds to peripheral blood antibody
sequences from HIV-infected donors (n=4). (A) Peripheral blood antibody sequences were grouped by HCDR3 length (in amino acids) and the
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36750reading frame 2 (RF2) has been shown to be the most common
reading frame in the overall repertoire [30,31,34,36,43], however,
there was a significantly increased preference for RF2 in long
HCDR3s in the peripheral blood antibody repertoire of Group 1
and Group 2 healthy donors (Figure 4A, left panel; p,0.001) and
in HIV-infected donors (Figure 4A, right panel; p,0.05). A
significant increase in RF2 use was also seen in very long HCDR3s
in both healthy and HIV-infected donors (Figure 4A; p,0.001
and p,0.01, respectively). Although this reading frame is
identified by IMGT as RF2, alternate methods of determining
the reading frame, which are based on analysis of the amino acid
sequence instead of the nucleotide sequence, produce a different
reading frame nomenclature. The reading frame identified as RF2
by IMGT would be identified as RF1 using the alternate
‘‘functional’’ reading frame determination system. To keep
confusion to a minimum, the IMGT nomenclature will be used
for the remainder of this report. The increased RF2 use in long
HCDR3s was unexpected because alternating the reading frame
of the D gene should not affect the overall sequence length
significantly. However, when analyzing the peripheral blood
repertoire of Group 1 and Group 2 healthy donors, we discovered
that the frequency of RF2 in the longest HCDR3s (Figure 4B, left
panel; 69%) was over twice the frequency of RF2 in the shortest
HCDR3s (28%). A similar pattern was seen in HIV-infected
individuals (Figure 4B, right panel).
We next considered whether RF2 was selected more frequently
in long HCDR3s because use of RF2 may have allowed for more
efficient in-frame recombination with the highly preferred JH6
gene. Examination of long HCDR3s in Group 1 and Group 2
healthy donors showed a similarly strong preference for RF2
(74%, r
2=0.55) in the longest HCDR3s of recombinants that did
not use the JH6 gene (Figure 4C, top left panel) than was seen in
the total repertoire. The same trend also was seen in sequences
that used JH6 (Figure 4C, bottom left panel; 75%, r
2=0.44). A
similar pattern of RF2 use in the presence or absence of JH6 also
was seen in cells from the HIV-infected subjects (Figure 4C, right
panels). Thus, the observed RF2 preference in long HCDR3s was
not primarily due to the need to form in-frame recombinations
with JH6.
Antibodies with long, hydrophobic HCDR3s often possess
autoreactive properties [38–41], and RF2 has been shown to be
preferred in the antibody repertoire likely due to increased tyrosine
frequency and lower hydrophobicity than other reading frames
[43,44]. Diversity genes in the D2 and D3 families are enriched for
tyrosine residues, although the three D genes with the highest
tyrosine content (D3-10, D3-16 and D3-22) were not among the
preferred D genes (data not shown). We next analyzed the
frequency of hydrophobic residues (Figure 4D) and the grand
average of hydropathicity (GRAVY, Figure 4E) of each functional
reading frame for the D2 and D3 families, with special attention
paid to the three germline D genes that were found most often in
long HCDR3s (designated by filled circles). Although the broader
results validate previous data (namely that RF2 is much less
hydrophobic than other reading frames), RF2 of the three
preferred germline genes is not substantially less hydrophobic
than RF2 of the other, non-preferred, D2/D3 gene members.
Thus, although hydrophobicity and tyrosine frequency may drive
the overwhelming prominence of RF2 in the normal antibody
repertoire, they do not seem to account for the strong preference
for the three highly preferred D genes in the long HCDR3
repertoire.
Amino Acid Residues Critical to Binding and
Neutralization of HIV by Broadly Neutralizing Antibodies
PG9 and PG16 are Encoded by JH6 and D3-3 Germline
Genes
The broadly neutralizing HIV antibodies PG9 and PG16
contain the longest HCDR3s of any antigen-specific human
monoclonal antibodies described to date [4]. We considered the
genetic basis for development of these unusual antibodies in light
of the information presented above on the typical origin of long
HCDR3s. These clonally related antibodies both possess HCDR3
regions containing 30 amino acids, which is twice the mean
HCDR3 length in the total repertoire. Remarkably, both PG9 and
PG16 antibodies use D3-3, one of the three D genes highly
preferred in long HCDR3s, and JH6. Further, both antibodies
position the diversity gene in RF2. We performed amino acid
sequence alignments with PG9 or PG16 and the corresponding
germline D and J genes (Figure 5). Based on previous studies [7],
we identified eight critical residues in these antibodies for which
a $10-fold decrease in either binding or neutralization occurred
when those single amino acids were mutagenized. Interestingly, six
of the eight critical residues were encoded by the germline
sequence of the D and J genes. Although two additional crucial
residues appear to be encoded by N-addition, it is impossible to
rule out the possibility that these residues are the consequence of
a post-recombination insertion event. Thus, the molecular basis
for development of these most broadly neutralizing antibodies for
HIV using very long HCDR3s was not a rare occurrence of
unusual mutations. Instead, these antibodies were derived from
a typical, almost canonical, selection of a D3-3 gene using RF2
and JH6, and much of the high affinity of these antibodies derives
from interactions mediated by unmutated germline-encoded
residues.
Discussion
Althoughdesigningastrategyforselectingorinducingantibodies
with long HCDR3s might be a groundbreaking step for vaccine
design,verylittleisknownaboutthegeneticoriginofsuchantibodies.
Two general models have been proposed for the generation of
antibodieswithlongHCDR3s.First,itispossiblethatlongHCDR3s
are generated through the introduction of multiple short insertion
eventsduringthesomatichypermutationprocess[25,27].Indeed,we
haveshownrecentlythatageneticinsertionwasacriticalfeaturethat
mediatedaffinitymaturationandacquisitionofneutralizingpotency
average N-addition length and P-addition length (both in nucleotides) was calculated for each HCDR3 length group. The mean length 6 SEM is
shown. Regression analysis of N-addition length produced a non-linear, exponential curve of best fit. Regression analysis of P-addition length
produced a linear best fit. (B) Peripheral blood antibody sequences were grouped by HCDR3 length and the frequency of sequences encoding either
diversity gene family 2 (D2) or diversity gene family 3 (D3) was calculated for each HCDR3 length group. The mean frequency of D2/D3 gene family
use 6 SEM for each HCDR3 length group is shown. Regression analysis produced a non-linear, sigmoidal curve of best fit. (C) Peripheral blood
antibody sequences were grouped by HCDR3 length and the frequency of sequences encoding joining gene 6 (JH6) was calculated for each HCDR3
length group. The mean frequency of D2/D3 gene family use 6 SEM for each HCDR3 length group is shown. Regression analysis produced a non-
linear, sigmoidal curve of best fit. (D) The frequency of sequences encoding both the JH6 germline gene and D2/D3 germline gene family members
was determined for each HCDR3 length group. The mean frequency of JH6/D2/D3 gene family use 6 SEM for each HCDR3 length group is shown.
Non-linear regression analysis produced a sigmoidal curve of best fit.
doi:10.1371/journal.pone.0036750.g003
Genetic Analysis of Long CDR3 Antibodies
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36750Genetic Analysis of Long CDR3 Antibodies
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e36750forahumanantibodythatinhibitsinfluenzavirus[45],althoughthis
wasashortinsertionthatdidnotcausealongHCDR3.Alternatively,
it is possible that long HCDR3s could be created at the time of
recombinationthroughacombinationofextensiveincorporationof
non-templated nucleotides during N- and P-addition and the
selective use of longer germline gene segments. In this setting, the
extended length of the HCDR3 would be established without the
need for theaffinity maturation process.In this study, wefound that
antibodies containing long HCDR3s are created primarily at
recombination and not through affinity maturation. In addition, we
identified several genetic features that are frequently seen in
antibodies with long HCDR3s but are uncommon in the rest of the
antibody repertoire. Finally, analysis of long HCDR3 encoding
antibodysequencesfromHIV-infecteddonorsproducedresultsthat
closely mirrored those from healthy donors. These results suggested
that antibodies withlong HCDR3sin HIV-infected individuals also
typically were generated atthe time ofrecombination.
These data show that increased HCDR3 length does not
correlate with either increased mutation count or insertion
frequency in the peripheral blood antibody population, although
mutation count and insertion frequency are themselves strongly
correlated. Further, these studies demonstrate the presence of B
cells with receptors incorporating long HCDR3s in the naı ¨ve cell
population. In fact, the naı ¨ve B cell subset contained a higher
proportion of long HCDR3s than did the affinity-matured
memory B cell population, suggesting that long HCDR3s are
produced independent of the affinity maturation process. Togeth-
er, the lack of correlation between increased HCDR3 length and
increased number of insertions arising during affinity maturation
and the presence of a sizeable fraction of long HCDR3s in the
memory cell population strongly indicate that long HCDR3s are
not primarily generated by repeated rounds of affinity maturation.
We also examined several events that occur during the
recombination process and discovered many correlations between
these molecular features of recombination and increased HCDR3
length. First, we found that increased number of nucleotides
introduced by N- or P-addition both correlated with increased
HCDR3 length. Next, we found that germline diversity genes in
the D2/D3 family and the germline joining gene JH6 were highly
favored in long HCDR3s. In fact, over half of all of the longest
HCDR3s used both of these germline sequence elements, while
fewer than 5% of the shortest HCDR3s contained both sequence
elements. Finally we discovered, somewhat surprisingly, that RF2
was highly preferred in long HCDR3s. Previous work by several
groups has indicated that long, hydrophobic HCDR3s often
possess autoreactive properties [38–41], so it seems likely that RF2
is used preferentially primarily because of the reduced hydropho-
bicity profile compared to other reading frames.
The observation that long HCDR3s are composed of conserved
sequence elements is of critical importance for two reasons. First,
these findings provide information that might be used in the design
of strategies to selectively induce expansion of particular B cells
encoding antibodies with long HCDR3s. Since long HCDR3s are
generated using a limited set of germline gene segments, and since
Figure 4. Long HCDR3s preferentially use reading frames (RF) that result in reduced hydrophobicity. (A) Peripheral blood antibody
sequences from Group 1 and Group 2 healthy donors (left panel) or HIV-infected donors (right panel) were assembled into three HCDR3 length
groups: (1) all HCDR3s; (2) HCDR3s of at least 24 amino acids; and (3) HCDR3s of at least 28 amino acids. (B) The percentage of sequences within each
HCDR3 group using reading frame 2 of the diversity gene (RF2) was calculated for each HCDR3 length group. Non-linear regression analysis produced
a sigmoidal curve of best fit (r
2=0.84). (C) Sequences that do not encode the joining gene JH6 (top panel) or do encode JH6 (bottom panel) were
grouped by HCDR3 length and RF2 use within each HCDR3 length group was determined. The mean frequency 6 SEM is shown. Non-linear
regression analysis produced a sigmoidal curve of best fit. (D) The percentage of hydrophobic residues was calculated for each reading frame of every
functional (lacking stop codons) diversity gene in the D2 and D3 germline gene families. The mean percentage 6 SEM is shown for each reading
frame. The RF2 hydrophobicity of the diversity genes which were shown to be increased in long HCDR3s are indicated by filled circles. The p values
were determined using a Student’s two-tailed t-test. (E) The grand average of hydropathicity (GRAVY) was calculated for each functional reading
frame of each D2 and D3 gene. A positive GRAVY score indicates hydrophobicity, and a negative GRAVY score indicates hydrophilicity. The mean
GRAVY score 6 SEM is shown for each reading frame. The RF2 GRAVY scores of the diversity genes that were shown to be increased in long HCDR3s
are indicated by filled circles. The p values were determined using Student’s two-tailed t-test. All statistically significant differences are indicated.
*=p,0.05, **=p,0.01, ***=p,0.001.
doi:10.1371/journal.pone.0036750.g004
Figure 5. Amino acid residues in JH6 and RF2 of D3-3 germline gene segments are critical to binding and neutralization of HIV by
long HCDR3-containing antibodies PG9 and PG16. The HCDR3 amino acid sequences of HIV-specific mAbs PG9 and PG16 are shown aligned
to the amino acid sequences of germline D3-3 and JH6 genes. Dashes in the alignments indicate conservation with the respective PG antibody.
Residues shown to be critical to binding or neutralization of HIV, defined as $10-fold decrease in either binding or neutralization when mutagenized
[5,24] are indicated by filled circles.
doi:10.1371/journal.pone.0036750.g005
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immunogens designed to target these conserved sequence elements
might induce an antibody response that is enriched in antibodies
containing long HCDR3s. Second, knowledge of conserved
genetic elements present in the majority of long HCDR3s provides
a starting point for affinity maturation of these antibodies. For
example, it has been suggested that one route to development of
an HIV vaccine would be to identify structures of neutralizing
epitopes and design immunogens that mimic these epitopes, with
the goal of eliciting an antibody response focused on the desired
neutralizing epitope [46–49]. An alternative to this approach has
been proposed, however, which consists of identifying the
structural and genetic components of potently neutralizing
antibodies and designing immunogens that gradually and specif-
ically induce desired affinity maturation events that result pro-
duction of broadly neutralizing antibodies. In effect, this alterna-
tive process would involve rationally guiding the affinity
maturation process through the selective use of sequential
immunizations [5]. This strategy would require detailed knowl-
edge not only of the desired final product, in this case a PG9- or
PG16-like broadly neutralizing antibody, but also of the genetic
characteristics of the naı ¨ve predecessors of the desired broadly
neutralizing antibody. The work presented here provides a sub-
stantial step toward realization of this alternative method of
vaccine development. Until this study, little was known about the
process of generating antibodies with long HCDR3s or the genetic
characteristics of the naı ¨ve predecessors of such antibodies. We
have identified conserved genetic elements in the long HCDR3
antibody population that form a potential starting point from
which rationally guided affinity maturation may begin.
In the case of mAbs PG9 and PG16, this potential is especially
enticing. Since many of the residues in these mAbs that are critical
for binding and neutralization are encoded in the germline gene
sequence, little affinity maturation may be necessary to produce
a potently neutralizing antibody. In fact, all but two residues
identified in PG9 and PG16 as critical to binding and neutrali-
zation were present in the germline D3-3 or JH6 genes, and those
additional critical residues were generated by random N-addition.
Accordingly, we suggest that it is highly likely that there are naı ¨ve
antibodies in HIV-unexposed individuals that use D2/3 and J6
gene segments and by random happenstance of N-addition,
encode many of the residues critical to PG-like neutralization.
Thus, while germline reversions of PG9 and PG16 are non-
neutralizing [5], it is possible that the naive predecessors of PG-like
antibodies will require only limited affinity maturation to gain
neutralization capacity. If this is the case, efforts should be focused
on selective induction of these rare antibodies containing long
HCDR3s, rather than sequential immunization strategies to
‘‘build up’’ long HCDR3s with somatic insertions.
In summary, we have identified the primary genetic basis of
development of antibodies containing long HCDR3s. These
antibodies are present in naı ¨ve populations, indicating that affinity
maturation is not necessary to produce such antibodies. Further,
we have identified conserved genetic features of such antibodies,
providing a potential pathway for selective induction of antibodies
containing long HCDR3s.
Methods
Sample Preparation and Sorting
Peripheral blood was obtained from healthy adult donors
following informed consent, under a protocol approved by the
Vanderbilt Institutional Review Board. Mononuclear cells from
the blood of four donors were isolated by density gradient
centrifugation with Histopaque 1077 (Sigma). Prior to staining, B
cells were enriched by paramagnetic separation using microbeads
conjugated with antibodies to CD19 (Miltenyi Biotec). Enriched B
cells were washed twice with PBS/5% FBS and stained with the
following antibodies conjugated to fluorophores: CD19-PerCP-
Cy5.5, CD27-APC, IgM-PE, IgG-FITC, CD14-Horizon V450
and CD3-Horizon V450 (Becton Dickinson). Cells from particular
B cell subsets were sorted as separate populations on a high speed
sorting cytometer (FACSAria III; Becton Dickinson) using the
following phenotypic markers, naı ¨ve B cells: CD19
+/CD27
2/
IgM
+/IgG
2/CD14
2/CD3
2, IgM memory B cells: CD19
+/
CD27
+/IgM
+/IgG
2/CD14
2/CD3
2 and IgG memory B cells:
CD19
+/CD27
+/IgM
2/IgG
+/CD14
2/CD3
2. Following flow cy-
tometric sorting, total RNA was isolated from each sorted cell
subset using a commercial RNA extraction kit (RNeasy; Qiagen)
and stored at 280uC until analysis.
cDNA Synthesis and PCR Amplication of Antibody Genes
RT-PCR primers were originally described by the BIOMED-2
consortium [50] and were slightly modified to suit amplification
for large-scale parallel pyrosequencing (454 Sequencing; 454 Life
Sciences/Roche). 100 ng of each total RNA sample and 10 pmol
of each RT-PCR primer (Table S1) were used in duplicate 50 ml
RT-PCR reactions using the OneStep RT-PCR system (Qiagen).
Thermal cycling was performed in a BioRad DNA Engine PTC-
0200 thermal cycler using the following protocol: 50uC for 30:00,
95uC for 15:00, 35 cycles of (94uC for 0:45, 58uC for 0:45, 72uC
for 2:00), 72uC for 10:00. cDNA synthesis and amplification were
verified by agarose gel electrophoresis before duplicate RT-PCR
reactions were pooled. 5 ml of each pooled RT-PCR reaction was
used as template for 100 ml 454-adapter PCR reactions, which
were carried out in quadruplicate. 20 pmol of each 454-adapter
primer (Table S1) and 0.25 units of AmpliTaq Gold polymerase
(Applied Biosystems) were used for each reaction. Thermal cycling
was performed in a BioRad DNA Engine PTC-0200 thermal
cycler using the following protocol: 95uC for 10:00, 10 cycles of
(95uC for 0:30, 58uC for 0:45, 72uC for 2:00), 72uC for 10:00.
Amplification was verified by agarose gel electrophoresis before
quadruplicate 454-adapter PCR reactions were pooled.
Amplicon Purification and Quantification
Amplicons were purified from the pooled 454-adapter PCR
reactions using the Agencourt AMPure XP system (Beckman
Coulter Genomics). Purified amplicons were analyzed on a 2%
agarose gel to verify complete primer removal before quantifica-
tion using a Qubit fluorometer (Invitrogen).
Amplicon Nucleotide Sequence Analysis
The size and quality of the DNA libraries was evaluated on an
Agilent Bioanalyzer 2100 using the DNA 7500 Labchip (Agilent).
The samples then were diluted to a working concentration of
1610
6 molecules per mL. Quality control of the amplicon libraries
and emulsion-based clonal amplification and sequencing on the
454 Genome Sequencer FLX Titanium system were performed by
the W. M. Keck Center for Comparative and Functional
Genomics at the University of Illinois at Urbana-Champaign,
according to the manufacturer’s instructions (454 Life Sciences).
Signal processing and base calling were performed using the
bundled 454 Data Analysis Software version 2.5.3 for amplicons.
Antibody Sequence Analysis
Nucleotide sequences were compared to the reference se-
quences from IMGT, the international ImMunoGeneTics in-
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IMGT/HighV-QUEST, a web portal allowing the analysis of
thousands of sequences on IMGT/V-QUEST [52]. IMGT output
was parsed into a custom MySQL database for further analysis.
Database administration and querying were performed with
Navicat for MySQL (Navicat). Antibody sequences returned from
IMGT were considered to be ‘‘high-quality’’ antibody sequences if
they met the following requirements: sequence length of at least
300 nt; identified variable and joining genes; an intact, in-frame
recombination; and absence of stop codons or ambiguous
nucleotide calls within the reading frame. HCDR3 length was
determined using the IMGT numbering system.
Statistical Analysis
All statistical analysis was performed using Graphpad Prism
software.
Supporting Information
Figure S1 Skewed germline gene usage in naı ¨ve anti-
bodies containing long or very long HCDR3s. Peripheral
blood antibody sequences from the naı ¨ve subset of Group 1 (n=4)
healthy donors were assembled into the following three groups by
HCDR3length:(1)allHCDR3s,whichcontainsallsequencesofany
HCDR3 length; (2) long HCDR3s, which contains only sequences
withaHCDR3length$24aminoacids;and(3)verylongHCDR3s,
which contains only sequences with a HCDR3 length $28 amino
acids.Thefrequencyofeachgermlinevariablegenefamily,diversity
gene family, and joining gene was determined for each HCDR3
length group. The mean frequency 6 SEM is shown. All HCDR3
lengths were calculated using the IMGT numbering system. The p
values were determined using a two-way ANOVA with Bonferroni
post-tests. All statistically significant differences are indicated.
*=p,0.05, **=p,0.01, ***=p,0.001.
(TIF)
Figure S2 Skewed germline gene usage in IgM memory
antibodies containing long or very long HCDR3s.
Peripheral blood antibody sequences from the IgM memory
subset of Group 1 (n=4) healthy donors were assembled into the
following three groups by HCDR3 length: (1) all HCDR3s, which
contains all sequences of any HCDR3 length; (2) long HCDR3s,
which contains only sequences with a HCDR3 length $24 amino
acids; and (3) very long HCDR3s, which contains only sequences
with a HCDR3 length $28 amino acids. The frequency of each
germline variable gene family, diversity gene family, and joining
gene was determined for each HCDR3 length group. The mean
frequency 6 SEM is shown. All HCDR3 lengths were calculated
using the IMGT numbering system. The p values were de-
termined using a two-way ANOVA with Bonferroni post-tests. All
statistically significant differences are indicated. *=p,0.05,
**=p,0.01, ***=p,0.001.
(TIF)
Figure S3 Skewed germline gene usage in IgG memory
antibodies containing long or very long HCDR3s.
Peripheral blood antibody sequences from the IgG memory subset
of Group 1 (n=4) healthy donors were assembled into the
following three groups by HCDR3 length: (1) all HCDR3s, which
contains all sequences of any HCDR3 length; (2) long HCDR3s,
which contains only sequences with a HCDR3 length $24 amino
acids; and (3) very long HCDR3s, which contains only sequences
with a HCDR3 length $28 amino acids. The frequency of each
germline variable gene family, diversity gene family, and joining
gene was determined for each HCDR3 length group. The mean
frequency 6 SEM is shown. All HCDR3 lengths were calculated
using the IMGT numbering system. The p values were de-
termined using a two-way ANOVA with Bonferroni post-tests. All
statistically significant differences are indicated. *=p,0.05,
**=p,0.01, ***=p,0.001.
(TIF)
Figure S4 Frequency of D gene use in long and very long
HCDR3s. Antibody sequences from Group 1 healthy donors
(n=4) were assembled into the following three groups by HCDR3
length: (1) all HCDR3s, which contains all sequences of any
HCDR3 length; (2) long HCDR3s, which contains only sequences
with a HCDR3 length $24 amino acids (at least two standard
deviations above the mean HCDR3 length for the entire
repertoire); or (3) very long HCDR3s, which contains only
sequences with a HCDR3 length $28 amino acids (at least three
standard deviations above the mean). The frequency of diversity
gene use in each of the three groups was determined for Group 1
healthy donor sequences (A). For the diversity genes that showed
significant increases in (A), frequency was calculated for the naive
(B), IgM memory (C), and IgG memory (D) subsets from the same
Group 1 donors. The mean frequency 6 SEM is shown. All
HCDR3 lengths were calculated using the IMGT numbering
system. The p values were determined using a two-way ANOVA
with Bonferroni post tests. All statistically significant differences
are indicated. *=p,0.05, **=p,0.01, ***=p,0.001.
(TIF)
Figure S5 Limited preference for isolated use of D2/D3
or JH6 in the longest HCDR3s. Peripheral blood antibody
sequences from Group 1 (n=4) and Group 2 (n=3) healthy
donors were grouped by HCDR3 length (in amino acids) and the
frequency of (A) sequences encoding germline genes from the D2
or D3 families but not JH6 or (B) sequences encoding JH6 but not
either of the D2 or D3 families. The mean frequency 6 SEM is
shown. All HCDR3 lengths were calculated using the IMGT
numbering system.
(TIF)
Table S1 Primers used in RT-PCR and 454-Adapter
PCR. Multiplex identifiers (MIDs) are underlined. Forward
primers use MID7 and reverse primers use MID4 (Roche).
Additional complementarity between RT-PCR primers and 454-
Adapter PCR primers is identified in italics. All primer sequences
are in the 59 to 39 orientation.
(DOCX)
Table S2 Sequencing results from Group 2 healthy
donors and HIV-infected donors. Donor IDs with the format
100XX are HIV-infected donors. Donors with the format HD-
XXX and Subject 42 are Group 2 healthy donors. The number of
sequences includes only non-redundant, high-quality sequences.
(DOCX)
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